Eliprodil
http://dbpedia.org/resource/Eliprodil an entity of type: Thing
Eliprodil (codenamed SL-82.0715) is an NMDA antagonist drug candidate which selectively inhibits the NR2B (GLUN2B) subtype NMDA receptor at submicromolar concentrations. Eliprodil failed a Phase III clinical trial for the treatment of acute ischemic stroke in 1996, sponsored by Synthélabo Recherche.
rdf:langString
rdf:langString
Eliprodil
xsd:integer
18509947
xsd:integer
1110497832
rdf:langString
None
xsd:integer
20
xsd:integer
119431
xsd:integer
91784
xsd:integer
28564
xsd:integer
54708
xsd:integer
1
xsd:integer
1
xsd:integer
23
xsd:integer
1
xsd:integer
1
xsd:integer
1
xsd:integer
60703
rdf:langString
C1CNCCO
xsd:integer
1
rdf:langString
GGUSQTSTQSHJAH-UHFFFAOYSA-N
rdf:langString
YW62A6TW29
rdf:langString
changed
xsd:integer
461093042
rdf:langString
changed
xsd:integer
250
rdf:langString
Eliprodil (codenamed SL-82.0715) is an NMDA antagonist drug candidate which selectively inhibits the NR2B (GLUN2B) subtype NMDA receptor at submicromolar concentrations. Eliprodil failed a Phase III clinical trial for the treatment of acute ischemic stroke in 1996, sponsored by Synthélabo Recherche. NMDA receptors are a key component in mediating glutamate-induced excitotoxicity, and it is believed that NMDA antagonists would be neuroprotective after a stroke or other traumatic brain injury. After a traumatic brain injury, neurons become deprived of glucose and oxygen. These neurons quickly lose ATP and become depolarized, which releases glutamate. The extracellular buildup of glutamate triggers the overstimulation of AMPA and NMDA receptors. This, in turn, causes an influx of Na+ and Ca2+. Therefore, when NMDA receptors are activated, there is an increase in intracellular Ca2+ concentration. High Ca2+ causes fatal metabolic consequences, including neuronal cell death.
xsd:nonNegativeInteger
4309
xsd:string
119431-25-3
xsd:string
91784
xsd:string
28564
xsd:string
YW62A6TW29
xsd:string
60703